CD19 is a surface glycoprotein and it’s expression is specific to B cells and B-cell malignancies with no expression in hematopoietic stem cells. CD19 is crucial for the development and activation of B cells because it is involved in B-cell receptor-dependent and independent signaling. Loncastuximab is a monoclonal antibody targeting CD19. It shows antitumor activity and has potential application in non-Hodgkin’s lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).
Loncastuximab-SAP is a bonded toxin between a biotinylated recombinant humanized antibody to CD19 and the secondary conjugate Streptavidin-ZAP containing the ribosome-inactivating protein, saporin.
Loncastuximab-SAP eliminates cells expressing human CD19. All other cells are left untouched.
The following control is included for validating the specificity of the beta conjugate: BIgG-SAP Human (Cat. #IT-77)
This product is being offered as part of our Beta Testing program. It has saporin activity confirmed, peptide sequences published/confirmed, and/or antibody binding specificity published/confirmed. It has not been characterized or reported in scientific literature. The researcher who first publishes data* will receive a $500 credit for use on ATS products.
*Data subject to review by the scientific team at ATS. See complete details here.
keywords: loncastuximab, CD19, glycoprotein, B cell, B-cell, antitumor, non-Hodgkin’s lymphoma, NHL, diffuse large B-cell lymphoma, DLBCL